Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock Has Average Price Target of $10.25 According to Brokerages

by · The Markets Daily

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the seventeen research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $10.25.

Several brokerages have recently commented on CMPX. Guggenheim lowered their price objective on shares of Compass Therapeutics to $4.00 and set a “buy” rating for the company in a research note on Wednesday, September 23rd. Wall Street Zen cut Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Wedbush set a $4.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, September 23rd. Citizens Jmp decreased their price objective on shares of Compass Therapeutics to $4.00 and set a “market outperform” rating for the company in a report on Wednesday, September 23rd. Finally, Piper Sandler raised their target price on shares of Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th.

Read Our Latest Analysis on Compass Therapeutics

Compass Therapeutics Stock Up 4.0%

Shares of NASDAQ CMPX opened at $0.79 on Thursday. Compass Therapeutics has a 52 week low of $0.73 and a 52 week high of $6.88. The firm’s fifty day moving average is $1.46 and its 200 day moving average is $3.23. The company has a market cap of $141.64 million, a price-to-earnings ratio of -1.97 and a beta of 1.02.

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities research analysts anticipate that Compass Therapeutics will post -0.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CMPX. Palo Alto Investors LP purchased a new stake in shares of Compass Therapeutics in the 2nd quarter worth approximately $12,771,670. BlackRock Inc. bought a new position in Compass Therapeutics during the 2nd quarter valued at approximately $24,707,000. Squarepoint Ops LLC raised its stake in Compass Therapeutics by 1,906.9% during the second quarter. Squarepoint Ops LLC now owns 1,007,507 shares of the company’s stock valued at $2,206,000 after buying an additional 957,305 shares during the last quarter. Bank of America Corp DE raised its stake in Compass Therapeutics by 224.9% during the first quarter. Bank of America Corp DE now owns 865,613 shares of the company’s stock valued at $4,579,000 after buying an additional 599,179 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Compass Therapeutics during the second quarter valued at $1,147,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

(Get Free Report)

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.

Read More